Global Devices For Inhaled Medications Market

Global Devices for Inhaled Medications Market, By Application (Commercial & Household), By Region (North America, Europe, Asia Pacific, Middle East & Africa, and Latin America); Trend Analysis, Competitive Market Share & Forecast, 2020-2026

  • Published Date: January 2021
  • Report ID: BWC202
  • Available Format: PDF
  • Page: 178

Report Overview

The global Devices for Inhaled Medications market is expected to reach USD  million by 2026, growing at a CAGR of % during the forecast period (2020-2026).

Global Devices for Inhaled Medications Market Size – Industry Trends & Forecast Report 2026

The global Devices for Inhaled Medications market is expected to reach USD  million by 2026, growing at a CAGR of % during the forecast period (2020-2026). Devices such as nebulizers have been used in hospitals to deliver drugs more effectively with minimal side effects on patients; inhalers are widely used due to their integration with smart technology; the number of smokers is on the rise and air pollution is rapid On the rise, the lung disease epidemic is the driving force behind the growth of the global inhaler market. The use of smart technology in the production of smart inhalers paves the way for future market growth, and the growth trend of micro-devices contributes to the growth of the market.

Source: BlueWeave Consulting

 

Global Devices for Inhaled Medications Market Overview:

Lung-based drugs are usually provided to prevent or alleviate asthma attacks and other respiratory diseases. Inhaled drugs or directly inhaled drugs are an important part of the treatment of chronic lung diseases. Various drugs are available in inhaled form. After inhalation, the drug will quickly reach the respiratory tract and be less absorbed into the blood. Many devices deliver drugs directly to the airway. Metered-dose inhalers (MDI), dry powder inhalers, nebulizers, and soft mist inhalers are currently available for a variety of drugs. Combinations of inhaled drugs can be used for many chronic lung diseases, including asthma and COPD. 

 

Global Devices for Inhaled Medications Market Forecast and Trends

 

Growth Drivers

 

Rise in prevalence of respiratory diseases

The prevalence of respiratory illnesses (COPD, asthma, emphysema, etc.) is increasing, the demand for first aid drugs during sudden asthma attacks is increasing, and the demand for short-term effective drugs is rapidly increasing. Also, manufacturers will focus on developing advanced portable inhalers, and government awareness programs for COPD and asthma symptoms are expected to drive market growth.

 

Increasing geriatric population 

According to the US Census Bureau, the 2010 census found that there were 40.3 million US residents aged 65 and over, and as of July 1, 2019, there were more than 54 million. According to the United Nations, between 2015 and 2030, that number is estimated to increase by 56% of people aged 60 and over worldwide (from 901 million to more than 1.4 billion). Hence, this is because asthma is a widespread disease among people over 65. Asthma in older people can cause serious health problems if not properly treated. Senior population growth is expected to drive market growth over the forecast period. However, inadequate cost recovery policies and strict regulatory requirements are expected to hamper the growth of asthma and COPD market.

 

Restraints

 

High cost of some inhalation devices and treatment.

Over the past few decades, the prevalence and incidence of asthma have increased worldwide due to exposure to a variety of risk factors, mostly related to the environment and lifestyle, as well as genetic background. Also, there are significant differences in cost estimates between studies in the same country. For example, US estimates of the per capita cost of asthma differ by up to five times. Despite different conditions and numbers, many studies indicate that the indirect costs of asthma are at least as high as the direct costs.

 

Impact of COVID-19 in the industry

 

In 2020, patients with asthma and COPD appear to have increased their adherence to inhaler drugs during the Covid-19 era, according to a paper published by the Journal of Allergy and Clinical Immunology. Also, the number of inhalers prescribed by general practitioners in England rose in 2020 by 63% between February 2020 and March 2020, according to the National Health Service (NHS). Also, there are shortages of albuterol inhalers in certain areas of the world, such as the United Kingdom and the United States, because hospitals use them mostly for patients with COVID-19. Thus, during the projected era, Covid-19 increased the growth and prospects for COPD and asthma product manufacturers.

 

Global Devices for Inhaled Medications Market: By Device

 

Based on segmentation, the global Devices for Inhaled Medications market is categorized into Dry Powder Inhalers, Metered-Dose Inhalers, Nebulizers, and Soft Mist Inhaler. The meter dose inhaler segment held the major market share in 2019, owing to the factors such as inhalation route is the fastest and most effective method of delivering medications to the respiratory system during treatment of COPD and asthma.

 

 

Global Devices for Inhaled Medications Market: By Type

 

Based on segmentation, the global Devices for Inhaled Medications market is categorized into Preventive Inhaler, Reliever inhaler, Long-acting bronchodilators inhaler. Bronchodilators are drugs that relax the bands of the muscles that tighten around your airways. This opens the airway and lets your lungs move more air in and out of it. That allows you to breathe easier. Bronchodilators also help the lungs expel mucus. Open airways mean that mucus can also flow more easily and can be coughed up.

 

Global Devices for Inhaled Medications Market: By End-use

 

Among these during the forecast period, the home care segment is projected to report the highest growth rate due to the growing geriatric population, increasing per capita expenditure, and increasing knowledge of respiratory diseases. A Healthcare First organization report found that more than 3.4 million people in the U.S. are receiving qualified home health care services from Medicare because of the growing elderly population and the rising prevalence of chronic health problems in the country.

 

Global Devices for Inhaled Medications Market: By Application

 

Based on segmentation, the global Devices for Inhaled Medications market is categorized into Asthma and Chronic Obstructive Pulmonary Disease. Growing geriatric populations with chronic respiratory problems; and lifestyle changes. Also, the launch by pharmaceutical and biotechnology companies of new and innovative pulmonary devices in personalized shapes and sizes, the availability of auto-injectors, and the increase in research and development activities to develop novel oral and nasal drug formulations are some of the other significant factors that are likely to drive the market.

Source: BlueWeave Consulting

 

Global Devices for Inhaled Medications Market: Regional insights

The global Devices for Inhaled Medications market is segmented into five regions including North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America accounted for the major share of the market size of COPD and asthma devices in 2019 and this trend is expected to continue due to the widespread and early adoption of inhalers & nebulizers and large pools of respiratory disease patients. In addition, the Asia-Pacific region is expected to grow rapidly due to increased spending on healthcare, increased awareness of advanced portable COPD & asthma devices.

Source: BlueWeave Consulting

Recent Development

On July 7, 2020 - Novartis announced that Enerzair Breezhaler (QVM149; indacaterol acetate, glycopyrronium bromide and mometasone furoate [IND/GLY/MF]) has been approved by the European Commission (EC) as a maintenance treatment for asthma in adult patients not sufficiently managed by a long-acting beta2-a gonist (LABA) and high-dose inhaled corticosteroid (ICS) maintenance combination who have encountered one or more inhaled corticosteroids. The first LABA/Long-acting Muscarinic Antagonist (LAMA)/ICS fixed-dose combination available in the EU for these patients is Enerzair Breezhaler once a day.

On Aug 2017 - Propeller Health, a leading digital respiratory medicine solution, today announced the extension of its partnership with GSK in 2015, allowing both companies to plan for and conduct commercial activities using the clip-on sensor and software platform from Propeller for use with the ELLIPTA Inhaler from GSK. Continuing research and development activities will continue to gather data from the Propeller clip-on sensor and software interface used in combination with GSK's asthma and COPD respiratory medicines.

 

Competitive landscape

Key players for Devices for Inhaled Medications market includes3M Company, Agilent technologies, Aradigm corporation, Astrazeneca plc, Bespak, Beximo pharmaceuticals ltd., Boehringer ingelheimgmbh, Cipla inc., Drive devilbiss healthcare, GE healthcare, Glaxosmithkline, H&T presspart manufacturing ltd, Hovione, Mannkind corporation, Manta devices llc, Midascare, Novartis ag, Omega life sciences, Omron healthcare europeb.v, Philips n.v, Propeller health, Pulmatrix, inc, Savara inc, Spyryx biosciences inc, Teicos pharma ltd, Teijin limited, Teva respiratory llc, Vitalograph, and Other Players.

 

Scope of the Report

Attribute

Details

Years Considered

Historical data – 2015-2019

Base Year – 2019

Forecast – 2020 – 2026

Facts Covered

Revenue in USD Million

Market Coverage

China, Japan, South Korea, India, ASEAN, US, Canada, Germany, France, UK, Italy, Brazil, Mexico, Saudi Arabia, UAE & South Africa

Product/Service Segmentation

By Device, By type, application End User and region

Key Players

Key players for global Devices for Inhaled Medicationsmarket are3M Company, Agilent technologies, Aradigm corporation, Astrazeneca plc, Bespak, Beximo pharmaceuticals ltd., Boehringer ingelheimgmbh, Cipla inc., Drive devilbiss healthcare, GE healthcare, Glaxosmithkline, H&T presspart manufacturing ltd, Hovione, Mannkind corporation, Manta devices llc, Midascare, Novartis ag, Omega life sciences, Omron healthcare europeb.v, Philips n.v, Propeller health, Pulmatrix, inc, Savara inc, Spyryx biosciences inc, Teicos pharma ltd, Teijin limited, Teva respiratory llc, Vitalograph, and Other Players

 

By Type

Ø  Preventive Inhaler

Ø  Reliever inhaler

Ø  Long acting bronchodilators inhaler

By Device

Ø  Dry Powder Inhalers

Ø  Metered-Dose Inhalers

Ø  Nebulizers

Ø  Soft Mist Inhaler

 

By Application

Ø  Asthma

Ø  Chronic Obstructive Pulmonary Disease

By End Use

Ø  Clinic

Ø  Hospital

 

Ø  Home

Ø

By Region:

Ø  Asia Pacific

Ø  North America

Ø  Europe

Ø  Middle East & Africa

Ø  Latin America